The Influence Of GIP (Glucose-Dependent Insulinotropic Polypeptide) Infusion On Human Adipose Tissue: An In Vivo Study

Not Applicable

• Conditions: Adipose Tissue

• Registration Number: NCT00809029
• Lead Sponsor: Liverpool University Hospitals NHS Foundation Trust

Brief Summary

Study part-1

GIP (glucose-dependent insulinotropic polypeptide) is one of the two main incretin hormones secreted by specialized cells of the gastrointestinal tract in response to ingestion of nutrients. Data emerging from studies in animal models and cultured human fat cells support a physiological role for GIP in the adipose tissue metabolism which may contribute to the pathogenesis of obesity.

The proposed study will shed more light on the interactions between gut hormones and adipose tissue. For this pilot study, male subjects fulfilling the inclusion criteria will be given GIP or placebo infusions in a randomized manner. Fat tissue biopsies will be obtained from all subjects during both visits, once in the basal state (before the start of the peptide/placebo infusion) and then repeated at the end of the period of infusion.

Study part-2

Surgery represents the most effective therapeutic modality for morbid obesity. Resolution of type 2 diabetes mellitus (T2DM) has been consistently observed as an additional benefit of surgical treatment of obesity. The mechanisms underlying the dramatic effects of surgery on insulin sensitivity and β-cell function are poorly understood. Bariatric surgery (gastric bypass) promotes changes in the enteroendocrine system as a result of nutrient diversion from the physiological intestinal routes with subsequent profound modification of gut hormone secretion

We hypothesize that restoration of GIP action after bariatric procedures plays a cardinal role in the improvement and/or restoration of diabetes, we propose to study patients (both sex)with morbid obesity and T2DM within 3 months after their surgery. Their responses will be compared to those of BMI matched control subjects with normal glucose tolerance

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2008-12-15
• Study First Submitted QC: 2008-12-15
• Study First Posted: 2008-12-16
• Study Start: 2011-04
• Status Verified: 2011-12
• Last Update Submitted: 2011-12-20
• Last Update Posted: 2011-12-21
• Primary Completion: 2012-12
• Study Completion: 2012-12

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: Male
• Target Recruitment: 12

Inclusion Criteria

• Lean (BMI 20-25 kg/m2) subjects with normal glucose tolerance
• Obese (BMI >30 kg/m2) subjects also with normal glucose tolerance.
• Obese with impaired glucose tolerance
• Obese with diet controlled diabetes mellitus
• Morbid obesity, type diabetes and post bariatric surgery (study part 2)

Read More

Exclusion Criteria

• History of severe cardiac, hepatic or renal disease
• Thyroid dysfunction (hyper-or hypothyroidism), or other endocrine disturbance (acromegaly, growth hormone deficiency, hypoadrenalism or cortisol overproduction)
• Current malignant disease
• Known alcohol misuse
• Major psychiatric disease (including current use of antidepressants)
• History of major eating disorder (anorexia or bulimia nervosa)

Read More

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: CROSSOVER

Primary Outcome Measures

Name	Time	Method
To measure Lipoprotein lipase (LPL) and Hormone sensitive Lipase (HSL) activity in adipose tissue	Before and after 4 hours of infusion

Secondary Outcome Measures

Name	Time	Method
To determine the role of GIP in adipocytokine gene expression and secretion from human subcutaneous adipose tissue	Baseline and after 4 hours of continuous infusion

Trial Locations

Locations (1)

University Hospital Aintree; 🇬🇧 Liverpool, United Kingdom